Safety and efficacy of the nMARQ catheter for paroxysmal and persistent atrial fibrillation

Martin Vurma, Lam Dang, Hanspeter Brunner-La Rocca, Gabor Sutsch, Christine H. Attenhofer-Jost, Firat Duru, Christoph Scharf*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Web of Science)

Abstract

Circular irrigated radiofrequency ablation using the nMARQ catheter has recently been introduced for the treatment of atrial fibrillation (AF). The aim of this study is to report the safety and efficacy of catheter ablation using this technology in patients with paroxysmal and persistent AF. The data of a prospective registry describing the experience of a single operator using this technology on 327 consecutive patients were analysed. The mean procedure time was 69 +/- 22 min for paroxysmal AF (n = 228) and 75 +/- 23 min for persistent AF (n = 97). Follow-up was available for 206 (63%) patients for 6 +/- 5 months (range 1-23, median 3.3). Single procedure success off antiarrhythmic drugs was 75% in paroxysmal AF and 52% in persistent AF. Including the 5% redo cases and those on antiarrhythmic medication, freedom from AF was documented in 90 and 83% of paroxysmal and persistent AF patients, respectively. There were no serious complications in the first 325 patients, but the last two consecutive patients (0.6%) developed atrio-oesophageal fistulas and had a fatal outcome. The catheter has been recalled from market. The nMARQ catheter is a highly effective tool for treatment of paroxysmal and persistent AF. Nevertheless, the occurrence of life-threatening oesophageal fistulas is of major concern and requires further investigation.
Original languageEnglish
Pages (from-to)1164-1169
JournalEP Europace
Volume18
Issue number8
DOIs
Publication statusPublished - Aug 2016

Keywords

  • Atrial fibrillation
  • Ablation
  • Pulmonary vein isolation
  • nMARQ
  • Atrio-oesophageal fistula

Cite this